The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Portrait of Daniel Förnvik. Photo

Daniel Förnvik

Associate professor

Portrait of Daniel Förnvik. Photo

Analysis of mammograms using artificial intelligence to predict response to neoadjuvant chemotherapy in breast cancer patients : proof of concept

Author

  • I. Skarping
  • M. Larsson
  • D. Förnvik

Summary, in English

Objectives: In this proof of concept study, a deep learning–based method for automatic analysis of digital mammograms (DM) as a tool to aid in assessment of neoadjuvant chemotherapy (NACT) treatment response in breast cancer (BC) was examined. Methods: Baseline DM from 453 patients receiving NACT between 2005 and 2019 were included in the study cohort. A deep learning system, using the aforementioned baseline DM, was developed to predict pathological complete response (pCR) in the surgical specimen after completion of NACT. Two image patches, one extracted around the detected tumour and the other from the corresponding position in the reference image, were fed into a classification network. For training and validation, 1485 images obtained from 400 patients were used, and the model was ultimately applied to a test set consisting of 53 patients. Results: A total of 95 patients (21%) achieved pCR. The median patient age was 52.5 years (interquartile range 43.7–62.1), and 255 (56%) were premenopausal. The artificial intelligence (AI) model predicted the pCR as represented by the area under the curve of 0.71 (95% confidence interval 0.53–0.90; p = 0.035). The sensitivity was 46% at a fixed specificity of 90%. Conclusions: Our study describes an AI platform using baseline DM to predict BC patients’ responses to NACT. The initial AI performance indicated the potential to aid in clinical decision-making. In order to continue exploring the clinical utility of AI in predicting responses to NACT for BC, further research, including refining the methodology and a larger sample size, is warranted. Key Points: • We aimed to answer the following question: Prior to initiation of neoadjuvant chemotherapy, can artificial intelligence (AI) applied to digital mammograms (DM) predict breast tumour response? • DMs contain information that AI can make use of for predicting pathological complete (pCR) response after neoadjuvant chemotherapy for breast cancer. • By developing an AI system designed to focus on relevant parts of the DM, fully automatic pCR prediction can be done well enough to potentially aid in clinical decision-making.

Department/s

  • Breast cancer prevention & intervention
  • LUCC: Lund University Cancer Centre
  • Breastcancer
  • Medical Radiation Physics, Malmö

Publishing year

2022

Language

English

Pages

3131-3141

Publication/Series

European Radiology

Volume

32

Issue

5

Document type

Journal article

Publisher

Springer

Topic

  • Cancer and Oncology

Keywords

  • Artificial intelligence
  • Breast neoplasms
  • Diagnostic imaging
  • Neoadjuvant therapy

Status

Published

Research group

  • Breast cancer prevention & intervention
  • Medical Radiation Physics, Malmö

ISBN/ISSN/Other

  • ISSN: 0938-7994